

Rab K Prinjha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3672348/publications.pdf>

Version: 2024-02-01

109
papers

14,442
citations

31902

53
h-index

26548

107
g-index

110
all docs

110
docs citations

110
times ranked

20855
citing authors

#	ARTICLE	IF	CITATIONS
1	Suppression of inflammation by a synthetic histone mimic. <i>Nature</i> , 2010, 468, 1119-1123.	13.7	1,377
2	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. <i>Nature</i> , 2011, 478, 529-533.	13.7	1,354
3	Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 27-41.	1.2	835
4	Remodeling of the Enhancer Landscape during Macrophage Activation Is Coupled to Enhancer Transcription. <i>Molecular Cell</i> , 2013, 51, 310-325.	4.5	616
5	Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. <i>Nature Chemical Biology</i> , 2015, 11, 189-191.	3.9	544
6	Candidate Single-Nucleotide Polymorphisms From a Genomewide Association Study of Alzheimer Disease. <i>Archives of Neurology</i> , 2008, 65, 45-53.	4.9	443
7	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015, 525, 538-542.	13.7	441
8	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. <i>Human Molecular Genetics</i> , 2009, 18, 767-778.	1.4	419
9	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. <i>Cancer Cell</i> , 2019, 36, 385-401.e8.	7.7	359
10	Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. <i>Nature</i> , 2014, 514, 513-517.	13.7	340
11	Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. <i>Cell</i> , 2014, 158, 989-999.	13.5	337
12	Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3827-3838.	2.9	318
13	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. <i>Science</i> , 2020, 368, 387-394.	6.0	274
14	Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. <i>Pain</i> , 2000, 88, 205-215.	2.0	271
15	Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7501-7515.	2.9	271
16	Suppression of the antiviral response by an influenza histone mimic. <i>Nature</i> , 2012, 483, 428-433.	13.7	269
17	Lysine methylation of the NF- κ B subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF- κ B signaling. <i>Nature Immunology</i> , 2011, 12, 29-36.	7.0	230
18	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. <i>Cancer Research</i> , 2015, 75, 5106-5119.	0.4	193

#	ARTICLE	IF	CITATIONS
19	Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis. <i>Cell</i> , 2018, 173, 260-274.e25.	13.5	186
20	Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. <i>Blood</i> , 2014, 123, 697-705.	0.6	184
21	Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2968-2972.	1.0	183
22	Selective inhibition of CD4 ⁺ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14532-14537.	3.3	177
23	Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1425-1439.	2.9	177
24	LRRK2 Gly2019Ser penetrance in Arab Berber patients from Tunisia: a case-control genetic study. <i>Lancet Neurology</i> , 2008, 7, 591-594.	4.9	172
25	BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models. <i>PLoS ONE</i> , 2013, 8, e72967.	1.1	167
26	The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8111-8131.	2.9	159
27	Structural analysis of human KDM5B guides histone demethylase inhibitor development. <i>Nature Chemical Biology</i> , 2016, 12, 539-545.	3.9	155
28	Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. <i>Journal of Experimental Medicine</i> , 2012, 209, 661-669.	4.2	147
29	Epigenetic drug discovery: breaking through the immune barrier. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 835-853.	21.5	136
30	The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 422-429.	0.5	134
31	Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1410-1424.	2.9	133
32	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. <i>Nature Communications</i> , 2019, 10, 2723.	5.8	126
33	Click chemistry enables preclinical evaluation of targeted epigenetic therapies. <i>Science</i> , 2017, 356, 1397-1401.	6.0	120
34	Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach. <i>ACS Chemical Biology</i> , 2018, 13, 2862-2867.	1.6	118
35	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1002-1017.	5.7	99
36	Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4317-4334.	2.9	94

#	ARTICLE	IF	CITATIONS
37	Functional interdependence of BRD4 and DOT1L in MLL leukemia. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 673-681.	3.6	92
38	8-Substituted Pyrido[3,4- <i>d</i>]pyrimidin-4(3 <i>H</i>)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1388-1409.	2.9	83
39	Lipid rafts mediate the interaction between myelin-associated glycoprotein (MAG) on myelin and MAG-receptors on neurons. <i>Molecular and Cellular Neurosciences</i> , 2003, 22, 344-352.	1.0	82
40	Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6151-6178.	2.9	81
41	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1190-1195.	1.3	78
42	Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5649-5673.	2.9	75
43	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 2422-2437.	1.6	72
44	Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. <i>Oncotarget</i> , 2015, 6, 21507-21521.	0.8	72
45	Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 695-709.	2.9	70
46	Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β^2 cells. <i>ELife</i> , 2014, 3, e04631.	2.8	69
47	Clinical progress and pharmacology of small molecule bromodomain inhibitors. <i>Current Opinion in Chemical Biology</i> , 2016, 33, 58-66.	2.8	69
48	BET bromodomain inhibition suppresses transcriptional responses to cytokine- and STAT signaling in a gene-specific manner in human monocytes. <i>European Journal of Immunology</i> , 2015, 45, 287-297.	1.6	67
49	A Chemical Probe for the ATAD2 Bromodomain. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 11382-11386.	7.2	67
50	The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes. <i>MedChemComm</i> , 2014, 5, 342-351.	3.5	66
51	Brd4 bridges the transcriptional regulators, Aire and P-TEFb, to promote elongation of peripheral-tissue antigen transcripts in thymic stromal cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4448-57.	3.3	62
52	Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4- <i>d</i>]pyrimidin-4(3 <i>H</i>)-one Derivatives. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1370-1387.	2.9	62
53	Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6056-6066.	3.3	61
54	SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. <i>Nature Communications</i> , 2018, 9, 5378.	5.8	60

#	ARTICLE	IF	CITATIONS
55	GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9045-9069.	2.9	59
56	Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome. <i>PLoS Biology</i> , 2015, 13, e1002316.	2.6	58
57	Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors. <i>Cancer Cell</i> , 2018, 33, 274-291.e8.	7.7	58
58	The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2795-2805.	0.3	55
59	GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 552-557.	1.3	54
60	Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1357-1369.	2.9	52
61	AÎ²1â€“42 reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: A quantitative analysis. <i>Journal of Neuroscience Methods</i> , 2008, 175, 96-103.	1.3	51
62	BRD4 Short Isoform Interacts with RRP1B, SIPA1 and Components of the LINC Complex at the Inner Face of the Nuclear Membrane. <i>PLoS ONE</i> , 2013, 8, e80746.	1.1	51
63	Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice. <i>Journal of Experimental Medicine</i> , 2015, 212, 1771-1781.	4.2	51
64	Influenza virus infection causes global RNAPII termination defects. <i>Nature Structural and Molecular Biology</i> , 2018, 25, 885-893.	3.6	48
65	Preclinical target validation using patient-derived cells. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 149-150.	21.5	46
66	Epigenetic Regulation of T Cell Memory: Recalling Therapeutic Implications. <i>Trends in Immunology</i> , 2020, 41, 29-45.	2.9	46
67	Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 714-746.	2.9	45
68	Coupling of T cell receptor specificity to natural killer T cell development by bivalent histone H3 methylation. <i>Journal of Experimental Medicine</i> , 2015, 212, 297-306.	4.2	43
69	The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9093-9126.	2.9	41
70	Progress in the Development of nonâ€“BET Bromodomain Chemical Probes. <i>ChemMedChem</i> , 2016, 11, 477-487.	1.6	40
71	Signaling function of PRC2 is essential for TCR-driven T cell responses. <i>Journal of Experimental Medicine</i> , 2018, 215, 1101-1113.	4.2	40
72	Design and Synthesis of a Highly Selective and <i>In Vivo</i> -Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9070-9092.	2.9	40

#	ARTICLE	IF	CITATIONS
73	BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells. <i>Stem Cell Research</i> , 2016, 17, 212-221.	0.3	38
74	Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9020-9044.	2.9	38
75	Immune disease-associated variants in gene enhancers point to BET epigenetic mechanisms for therapeutic intervention. <i>Epigenomics</i> , 2017, 9, 573-584.	1.0	37
76	Drawing on disorder: How viruses use histone mimicry to their advantage. <i>Journal of Experimental Medicine</i> , 2018, 215, 1777-1787.	4.2	37
77	Interrogating the Druggability of the 2-Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics. <i>ACS Chemical Biology</i> , 2016, 11, 2002-2010.	1.6	36
78	Advancements in the Development of non-BET Bromodomain Chemical Probes. <i>ChemMedChem</i> , 2019, 14, 362-385.	1.6	36
79	A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. <i>Journal of Experimental Medicine</i> , 2015, 212, 1551-1569.	4.2	35
80	Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10806-10833.	2.9	31
81	BET Inhibition Improves NASH and Liver Fibrosis. <i>Scientific Reports</i> , 2018, 8, 17257.	1.6	27
82	Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12200-12227.	2.9	26
83	GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1581-1587.	1.3	25
84	Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	25
85	Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: <sc>IUPHAR</sc> Review 11. <i>British Journal of Pharmacology</i> , 2014, 171, 4981-5010.	2.7	23
86	BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation. <i>Science Advances</i> , 2021, 7, .	4.7	23
87	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1002-1017.	5.7	23
88	Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5816-5840.	2.9	21
89	A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7506-7525.	2.9	19
90	Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3249-3281.	2.9	19

#	ARTICLE	IF	CITATIONS
91	Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8321-8336.	2.9	17
92	Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10711-10741.	2.9	17
93	Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10772-10805.	2.9	17
94	Combined noncanonical NF- κ B agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	17
95	BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo. <i>Antiviral Research</i> , 2018, 154, 158-165.	1.9	16
96	IFN- γ Drives Human Monocyte Differentiation into Highly Proinflammatory Macrophages That Resemble a Phenotype Relevant to Psoriasis. <i>Journal of Immunology</i> , 2021, 207, 555-568.	0.4	15
97	The "Histone Mimicry" by Pathogens. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2013, 78, 81-90.	2.0	14
98	Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5212-5241.	2.9	14
99	Identification of a Series of <i>N</i> -Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10742-10771.	2.9	14
100	Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2262-2287.	2.9	14
101	A Chemical Probe for the ATAD2 Bromodomain. <i>Angewandte Chemie</i> , 2016, 128, 11554-11558.	1.6	10
102	Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined Hypoxia and Pulmonary Inflammation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2224.	1.8	10
103	Bromodomain factor 5 is an essential regulator of transcription in <i>Leishmania</i> . <i>Nature Communications</i> , 2022, 13, .	5.8	8
104	Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1308-1317.	1.3	4
105	Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses. <i>International Journal of Cancer</i> , 2022, , .	2.3	3
106	Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins. <i>Scientific Reports</i> , 2017, 7, 12133.	1.6	2
107	Bromodomain Inhibitors Modulate Fc γ R-Mediated Mononuclear Phagocyte Activation and Chemotaxis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
108	Anti-inflammatory Effects of BET Protein Inhibition Through Modulation of Gene Transcription. , 2015, , 199-223.		1

#	ARTICLE	IF	CITATIONS
109	The Epigenetics of Autoimmunity and Epigenetic Drug Discovery. , 2018, , 297-320.		0